BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 15864481)

  • 1. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma.
    Vuylsteke RJ; Borgstein PJ; van Leeuwen PA; Gietema HA; Molenkamp BG; Statius Muller MG; van Diest PJ; van der Sijp JR; Meijer S
    Ann Surg Oncol; 2005 Jun; 12(6):440-8. PubMed ID: 15864481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma.
    Page AJ; Carlson GW; Delman KA; Murray D; Hestley A; Cohen C
    Am Surg; 2007 Jul; 73(7):674-8; discussion 678-9. PubMed ID: 17674939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
    Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
    Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node.
    Rossi CR; De Salvo GL; Bonandini E; Mocellin S; Foletto M; Pasquali S; Pilati P; Lise M; Nitti D; Rizzo E; Montesco MC
    Ann Surg Oncol; 2008 Apr; 15(4):1202-10. PubMed ID: 18165880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma?
    Frankel TL; Griffith KA; Lowe L; Wong SL; Bichakjian CK; Chang AE; Cimmino VM; Bradford CR; Rees RS; Johnson TM; Sabel MS
    Ann Surg Oncol; 2008 Sep; 15(9):2403-11. PubMed ID: 18626721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?
    Gajdos C; Griffith KA; Wong SL; Johnson TM; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
    Cancer; 2009 Dec; 115(24):5752-60. PubMed ID: 19827151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients.
    Roka F; Mastan P; Binder M; Okamoto I; Mittlboeck M; Horvat R; Pehamberger H; Diem E
    Eur J Surg Oncol; 2008 Jan; 34(1):82-8. PubMed ID: 17360144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
    Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
    Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.
    Debarbieux S; Duru G; Dalle S; BĂ©atrix O; Balme B; Thomas L
    Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
    MandalĂ  M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
    Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.
    Roka F; Kittler H; Cauzig P; Hoeller C; Hinterhuber G; Wolff K; Pehamberger H; Diem E
    Br J Cancer; 2005 Feb; 92(4):662-7. PubMed ID: 15700039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
    Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
    J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
    Nowecki ZI; Rutkowski P; Michej W
    Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma.
    Sabel MS; Griffith K; Sondak VK; Lowe L; Schwartz JL; Cimmino VM; Chang AE; Rees RS; Bradford CR; Johnson TM
    J Am Coll Surg; 2005 Jul; 201(1):37-47. PubMed ID: 15978442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.
    Kruper LL; Spitz FR; Czerniecki BJ; Fraker DL; Blackwood-Chirchir A; Ming ME; Elder DE; Elenitsas R; Guerry D; Gimotty PA
    Cancer; 2006 Nov; 107(10):2436-45. PubMed ID: 17058288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.
    Paek SC; Griffith KA; Johnson TM; Sondak VK; Wong SL; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
    Cancer; 2007 Jan; 109(1):100-8. PubMed ID: 17146784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node.
    Rivers AK; Griffith KA; Hunt KK; Degnim AC; Sabel MS; Diehl KM; Cimmino VM; Chang AE; Lucas PC; Newman LA
    Ann Surg Oncol; 2006 Jan; 13(1):36-44. PubMed ID: 16378156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.